Combination of somatostatin analogues and dexamethasone (antisurvival‐factor concept) with luteinizing hormone‐releasing hormone in androgen ablation‐refractory prostate cancer with bone metastasis

M. Koutsilieris,T. Dimopoulos,C. Milathianakis,J. Bogdanos,D. Karamanolakis,Nicholas Pissimissis,A. Halapas,P. Lembessis,A. Papaioannou,A. Sourla
DOI: https://doi.org/10.1111/j.1464-410X.2007.06958.x
2007-07-01
BJU International
Abstract:Michael Koutsilieris, Theodore Dimopoulos*, Constantine Milathianakis†, John Bogdanos, Dimitrios Karamanolakis, Nicholas Pissimissis, Antonis Halapas, Peter Lembessis, Andreas Papaioannou‡ and Antigone Sourla¶ Department of Experimental Physiology, Medical School, National & Kapodistrian University of Athens, Goudi-Athens, *Urology Clinic, Panagia General Hospital, Thessaloniki, †Urology Clinic, ‘Metaxa’ Anticancer Hospital, Piraeus, ‡Urology Clinic, Argos General Hospital, Argos, and ¶Endo/OncoResearch Laboratories, Diagnostic Medical Center, Athens, Greece
What problem does this paper attempt to address?